- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02961400
Improving Memory for Sleep Treatment Content With Text Messages
October 28, 2019 updated by: Allison Harvey, University of California, Berkeley
A drop off in improvement over the months and years after treatment is common.
One contributor may be poor memory for the contents of treatment.
This study seeks to determine whether text messages containing reminders of the content of sessions will improve treatment outcomes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The growth in the use of technology provides an opportunity to send reminders to participants via text messages.
The early studies on text messaging interventions indicate this approach is enjoyable for participants and has positive effects across a range of domains and treatment types.
Hence, this study will test whether text messages containing reminders of the content of sessions will improve treatment outcomes.
Two text messaging methods will also be tested.
One is to send text messages to remind participants of their goals (PUSH condition) and the second is to send text messages to remind participants to recall their goals (PULL condition).
This study will be conducted within the context of an NICHD-funded Randomized Controlled Trial (grant number R01-HD071065; protocol registration ID NCT01828320).
In R01-HD071065 adolescents ages 10-18 (n = 176) will receive either the Transdiagnostic Sleep and Circadian Intervention (TranS-C) or a Psychoeducation (PE).
At the 6-month follow-up assessment for R01-HD071065, participants will be randomized using 3 (PUSH text messages, PULL text messages, or no text messages) x 2 (TranS-C or PE) design.
At the 6-month follow-up assessment, a questionnaire will also be administered to establish baseline memory for treatment.
Participants will be sent text messages once per week until they return for the 12 month follow-up assessment for R01-HD071065.
At the 12 month follow-up assessment, participants will be asked to complete the same memory for treatment questionnaire completed at the 6 month follow-up assessment as well as a questionnaire evaluating the acceptability of the text message reminders.
This research is a first step toward identifying whether an inexpensive and ubiquitous technology (i.e., text messaging) can improve memory for treatment.
Study Type
Interventional
Enrollment (Actual)
176
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Berkeley, California, United States, 94720
- University of California, Berkeley
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Scoring within the lowest quartile of the Children's Morningness-Eveningness Preferences Scale (CMEP; 27 or lower) and a 7-day sleep diary showing a sleep onset time of of 10:40 pm or later for 10-13 year olds, 11 pm or later for 14-16 year olds, and 11:20 pm or later for 17-18 year olds at least 3 nights per week. Must have had the current pattern of late bedtimes for the last 3 months.
- 'At risk' in one of the five health domains: emotional, behavioral, social, physical, and cognitive. Emotional risk will be operationalized as a score of 4 or above on any of the following items on the Child Depression Rating Scale: Difficulty Having Fun, Social Withdrawal, Irritability, Depressed Feelings, Excessive Weeping, or a T-score of 61 or above on the Multidimensional Anxiety Scale for Children (MASC), based on age group (10-11 years, 12-15 year, 16-19 years) using the MASC-10 Profile. Behavioral risk will be operationalized as a Sensation Seeking Scale score greater than 3.93 for males ages 10-13, greater than 3.19 for females 10-13, greater than 4.07 for males 14-18, or greater than 3.19 for females 14-18; taking ADHD medication or Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADs) diagnosis of ADHD; current alcohol or substance abuse; or past alcohol or substance dependence. Social and cognitive risk will be defined as "worse" than others the teen's age in one or more social behavior from Child Behavior Checklist (CBCL) Section VI or failing one or more academic class from CBCL Section VII, respectively. Physical risk will be operationalized as a Physical Health Questionnaire-15 score of 4 or above, six or more days of school absences, or a BMI above the 85th percentile for the participant's sex and age.
- Age between 10 and 18 and living with a parent or guardian and and attending a class/job by 9am at least 3 days per week;
- English language fluency;
- Able and willing to give informed assent.
Exclusion Criteria:
- An active, progressive physical illness (e.g., cancer, respiratory disorder) or neurological degenerative disease directly related to the onset and course of the sleep disturbance;
- Evidence from clinical diagnosis or report by youth or parent of sleep apnea, restless legs or periodic limb movements during sleep. Youth presenting with provisional diagnoses of any of these disorders (e.g., sleep apnea) will be referred for a non-study polysomnography (PSG) evaluation at the parent's discretion and will be enrolled only if the diagnosis is disconfirmed;
- Mental retardation, autism spectrum disorder, or other significantly impairing pervasive developmental disorder. Based on previous recruitment experiences in a youth depression study, it is expected that this exclusion will be invoked very infrequently (once every few years);
- Bipolar disorder or schizophrenia or another current Axis I disorder if there is a significant risk of harm and/or decompensation if treatment of that comorbid condition is delayed as a function of participating in any stage of this study. Otherwise, all other comorbid psychiatric conditions will be allowed to (i) to maximize representativeness and (ii) because a byproduct may be that the treatment constitutes a helpful 'transdiagnostic' treatment for youth across psychiatric disorders.
- A medication-free group may be difficult to recruit and would likely be unrepresentative. Hence, participants will not be excluded on the basis of stable use of medications (> 4 weeks). The exception was use of hypnotics and other medications known to alter sleep (e.g., melatonin).
- History of substance dependence in the past six months;
- Current suicide risk sufficient to preclude treatment on an outpatient basis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PUSH text messages
Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
|
The intervention is designed to remind participants of treatment components.
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
|
EXPERIMENTAL: PULL text messages
Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
Text messages will request a response from the participant.
|
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
The intervention is designed to remind participants to recall treatment components.
|
OTHER: No text messages
No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
|
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total sleep time (TST) average on weeknights via Daily Sleep Diary
Time Frame: Measured at 6-months post-treatment
|
6mo TST
|
Measured at 6-months post-treatment
|
Total sleep time (TST) average on weeknights via Daily Sleep Diary
Time Frame: Measured at 12-months post-treatment
|
12mo TST
|
Measured at 12-months post-treatment
|
Average bedtime on weeknights measured via Daily Sleep Diary
Time Frame: Measured at 6-months post-treatment
|
6mo Avg Bedtime
|
Measured at 6-months post-treatment
|
Average bedtime on weeknights measured via Daily Sleep Diary
Time Frame: Measured at 12-months post-treatment
|
12mo Avg Bedtime
|
Measured at 12-months post-treatment
|
Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale
Time Frame: Measured at 6-months post-treatment
|
6mo CME
|
Measured at 6-months post-treatment
|
Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale
Time Frame: Measured at 12-months post-treatment
|
12mo CME
|
Measured at 12-months post-treatment
|
Patient Recall of Session Contents
Time Frame: Change from 6-months post-treatment to 12-months post-treatment
|
6-12mo Change in Patient Recall
|
Change from 6-months post-treatment to 12-months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleepiness scale
Time Frame: Measured at 6-months post-treatment
|
Embedded within the School Sleep Habits Survey
|
Measured at 6-months post-treatment
|
Sleepiness scale
Time Frame: Measured at 12-months post-treatment
|
Embedded within the School Sleep Habits Survey
|
Measured at 12-months post-treatment
|
Pittsburgh Sleep Quality Index
Time Frame: Measured at 6-months post-treatment
|
6mo PSQI
|
Measured at 6-months post-treatment
|
Pittsburgh Sleep Quality Index
Time Frame: Measured at 12-months post-treatment
|
12mo PSQI
|
Measured at 12-months post-treatment
|
Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary
Time Frame: Measured at 6-months post-treatment
|
6mo Weeknight-Weekend Differences
|
Measured at 6-months post-treatment
|
Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary
Time Frame: Measured at 12-months post-treatment
|
12mo Weeknight-Weekend Differences
|
Measured at 12-months post-treatment
|
Text Message Evaluation
Time Frame: Measured at 12-months post-treatment
|
Measure of the acceptability of receiving text messages
|
Measured at 12-months post-treatment
|
Child Behavior Checklist
Time Frame: Measured at 6-months post-treatment
|
Parent measure
|
Measured at 6-months post-treatment
|
Child Behavior Checklist
Time Frame: Measured at 12-months post-treatment
|
Parent measure
|
Measured at 12-months post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Useful and Utilized Questionnaire
Time Frame: Measured at 6-months post-treatment
|
6mo UUQ
|
Measured at 6-months post-treatment
|
Useful and Utilized Questionnaire
Time Frame: Measured at 12-months post-treatment
|
12mo UUQ
|
Measured at 12-months post-treatment
|
Daily Sleep Diary
Time Frame: Measured at 6-months post-treatment
|
total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps.
|
Measured at 6-months post-treatment
|
Daily Sleep Diary
Time Frame: Measured at 12-months post-treatment
|
total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps.
|
Measured at 12-months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Michael R Dolsen, University of California, Berkeley
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (ACTUAL)
December 1, 2017
Study Completion (ACTUAL)
December 1, 2018
Study Registration Dates
First Submitted
October 17, 2016
First Submitted That Met QC Criteria
November 8, 2016
First Posted (ESTIMATE)
November 11, 2016
Study Record Updates
Last Update Posted (ACTUAL)
October 29, 2019
Last Update Submitted That Met QC Criteria
October 28, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-02-4007_text_message
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Wake Disorders
-
Oregon State UniversityMonash University; Stanford University; American Academy of Sleep MedicineRecruitingSleep Initiation and Maintenance Disorders | Circadian Rhythm Sleep-Wake Disorders, Shift Work TypeUnited States
-
Vanda PharmaceuticalsActive, not recruitingNon 24 Hour Sleep Wake DisorderFrance
-
Vanda PharmaceuticalsCompletedNon-24-Hour-Sleep-Wake Disorder
-
Vanda PharmaceuticalsCompletedNon-24-Hour Sleep-Wake DisorderUnited States
-
Brigham and Women's HospitalActive, not recruitingSleep Disorders, Intrinsic | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular Sleep-Wake Syndrome | Shift...United States
-
University of Geneva, SwitzerlandCompletedNocturnal Leg Cramps | Sleep Wake Transition DisordersSwitzerland
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityRecruitingSleep Disorders, Intrinsic | Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular... and other conditionsUnited States
-
Mayo ClinicCompletedDelayed Sleep-Wake Phase DisorderUnited States
-
Vanda PharmaceuticalsCompletedNon-24-Hour Sleep-Wake DisorderUnited States
-
Vanda PharmaceuticalsCompletedNon-24-Hour Sleep-Wake DisorderUnited States, Germany
Clinical Trials on PUSH text messages
-
Friedrich-Alexander-Universität Erlangen-NürnbergPhilipps University Marburg Medical CenterCompleted
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
Children's Hospitals and Clinics of MinnesotaHealthPartners InstituteUnknownAsthmaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedSmoking | PregnancyUnited States
-
Medical University of South CarolinaRoswell Park Cancer InstituteCompleted
-
Auburn UniversityCompleted
-
Evidation HealthDefense Advanced Research Projects Agency; Army Research Office (ARO)Unknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Not yet recruitingHuman Papillomavirus Vaccines
-
Centre for Addiction and Mental HealthHealth CanadaCompleted
-
Columbia UniversityCompletedAtopic DermatitisUnited States